HK1083451A1 - N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion - Google Patents

N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion

Info

Publication number
HK1083451A1
HK1083451A1 HK06103425A HK06103425A HK1083451A1 HK 1083451 A1 HK1083451 A1 HK 1083451A1 HK 06103425 A HK06103425 A HK 06103425A HK 06103425 A HK06103425 A HK 06103425A HK 1083451 A1 HK1083451 A1 HK 1083451A1
Authority
HK
Hong Kong
Prior art keywords
biphenylcarboxamidesas
apolipoprotein
secretion
inhibitors
piperidine substituted
Prior art date
Application number
HK06103425A
Other languages
English (en)
Inventor
Meerpoel Lieven
Backx Leo Jacobus Jozef
Roevens Peter Walter Maria
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1083451A1 publication Critical patent/HK1083451A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
HK06103425A 2002-08-12 2006-03-17 N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion HK1083451A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078309 2002-08-12
PCT/EP2003/008694 WO2004017969A1 (en) 2002-08-12 2003-08-05 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Publications (1)

Publication Number Publication Date
HK1083451A1 true HK1083451A1 (en) 2006-07-07

Family

ID=31896911

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103425A HK1083451A1 (en) 2002-08-12 2006-03-17 N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion

Country Status (32)

Country Link
US (2) US20060040989A1 (hr)
EP (1) EP1536796B1 (hr)
JP (1) JP4559856B2 (hr)
KR (1) KR101052204B1 (hr)
CN (3) CN101165053A (hr)
AR (1) AR040968A1 (hr)
AT (1) ATE385796T1 (hr)
AU (1) AU2003250215B2 (hr)
BR (1) BR0313377A (hr)
CA (1) CA2494208C (hr)
CY (1) CY1107945T1 (hr)
DE (1) DE60319097T2 (hr)
DK (1) DK1536796T3 (hr)
EA (1) EA008061B1 (hr)
EG (1) EG25699A (hr)
ES (1) ES2301873T3 (hr)
HK (1) HK1083451A1 (hr)
HR (1) HRP20050103B1 (hr)
IL (1) IL166795A (hr)
IS (1) IS2726B (hr)
MX (1) MXPA05001712A (hr)
MY (1) MY136632A (hr)
NO (1) NO329308B1 (hr)
NZ (1) NZ538680A (hr)
PA (1) PA8579901A1 (hr)
PL (1) PL212405B1 (hr)
PT (1) PT1536796E (hr)
SI (1) SI1536796T1 (hr)
TW (1) TWI342775B (hr)
UA (1) UA79300C2 (hr)
WO (1) WO2004017969A1 (hr)
ZA (1) ZA200501225B (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
FR2883000B1 (fr) * 2005-03-14 2007-06-01 Merck Sante Soc Par Actions Si Derives de trifluoromethylbenzamide et leurs utilisations en therapeutique
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
EP3431602A1 (en) * 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) * 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
US20110054011A1 (en) * 2007-08-30 2011-03-03 Mccullagh Keith RNA Antagonist Compounds for the Modulation of FABP4/AP2
MX2010002885A (es) * 2007-09-20 2010-04-01 Amgen Inc Derivados de acido 1-(4-(bencilbenzamido)-bencil)-azetidin-3-carbo xilico y compuestos relacionados como moduladores de receptores de s1p para el tratamiento de trastornos inmunitarios.
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
SI3154967T1 (sl) 2014-06-16 2020-11-30 Johnson Matthey Public Limited Company, Postopki za pripravo alkiliranih arilpiperazinskih in alkiliranih arilpiperidinskih spojin, ki vključujejo nove intermediate

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4847271A (en) * 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5041432A (en) * 1987-01-30 1991-08-20 E. I. Du Pont De Nemours And Company Steroid derivatives useful as hypocholesterolemics
US5064856A (en) * 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
WO1993011782A1 (en) * 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
SG48855A1 (en) 1992-04-20 1998-05-18 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
US5510379A (en) * 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
GB9504066D0 (en) 1995-03-01 1995-04-19 Pharmacia Spa Phosphate derivatives of ureas and thioureas
TR199902579T2 (xx) * 1997-04-18 2000-01-21 Pfizer Inc. 4'-Triflorometil-Bifenil-2-Karboksilik asit (1,2,3,4-Tetrahidro-Izokinolin-6-�l)-Amid' in haz�rlanmas� i�in y�ntem ve ara�lar
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
WO2003002582A1 (en) * 2001-06-27 2003-01-09 Rs Tech Corp. New chiral salen catalyst and methods for the preparation of chiral compounds from racemic epoxides by using new catalyst
GB0129015D0 (en) * 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
ZA200501225B (en) 2006-07-26
SI1536796T1 (sl) 2008-08-31
EG25699A (en) 2012-05-22
HRP20050103A2 (en) 2006-09-30
KR20050026483A (ko) 2005-03-15
CN101165053A (zh) 2008-04-23
NO329308B1 (no) 2010-09-27
TWI342775B (en) 2011-06-01
ES2301873T3 (es) 2008-07-01
PA8579901A1 (es) 2005-03-03
IL166795A0 (en) 2006-01-15
UA79300C2 (en) 2007-06-11
US20060040989A1 (en) 2006-02-23
CN101165052B (zh) 2012-04-18
DE60319097D1 (de) 2008-03-27
EP1536796A1 (en) 2005-06-08
NO20050563L (no) 2005-01-31
US20090156623A1 (en) 2009-06-18
CA2494208A1 (en) 2004-03-04
JP4559856B2 (ja) 2010-10-13
IS2726B (is) 2011-03-15
TW200412954A (en) 2004-08-01
PL212405B1 (pl) 2012-09-28
PL373379A1 (en) 2005-08-22
CA2494208C (en) 2011-05-10
EA200500348A1 (ru) 2005-08-25
AU2003250215A1 (en) 2004-03-11
NZ538680A (en) 2006-01-27
US8258304B2 (en) 2012-09-04
PT1536796E (pt) 2008-05-13
BR0313377A (pt) 2005-07-12
AU2003250215B2 (en) 2009-01-22
CN101165052A (zh) 2008-04-23
ATE385796T1 (de) 2008-03-15
IS7622A (is) 2004-12-29
MXPA05001712A (es) 2005-04-19
EP1536796B1 (en) 2008-02-13
DE60319097T2 (de) 2009-06-04
WO2004017969A1 (en) 2004-03-04
EA008061B1 (ru) 2007-02-27
KR101052204B1 (ko) 2011-07-29
HRP20050103B1 (hr) 2013-09-30
DK1536796T3 (da) 2008-06-09
MY136632A (en) 2008-11-28
AR040968A1 (es) 2005-04-27
CN100366252C (zh) 2008-02-06
CN1674900A (zh) 2005-09-28
JP2006500371A (ja) 2006-01-05
IL166795A (en) 2010-11-30
CY1107945T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
HK1083451A1 (en) N-aryl piperidine substituted biphenylcarboxamidesas inhibitors of apolipoprotein B secretion
HK1072545A1 (en) Novel inhibitors of kinases
HK1080745A1 (en) Angiogenesis inhibitors
AU2002344567A1 (en) Heterocyclic amide compounds as apolipoprotein b inhibitors
AU2003298514A8 (en) Methods and compositions using cholinesterase inhibitors
HK1072362A1 (en) Methods of inducing terminal differentiation
AU2003251559A8 (en) Heterocyclic inhibitors of kinases
IL165887A0 (en) Novel tetrahydropyridine derivatives as renin inhibitors
AU2003217105A8 (en) Novel of cytokine inhibitors
EP1549316A4 (en) HAMMER OF TFGbeta
AU2003232848A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
EP1532133A4 (en) NF-: B INHIBITORS
EP1638565A4 (en) SUBSTITUTED PIPERIDINE COMPOUNDS AND METHOD OF USE THEREOF
AU2003299901A8 (en) Thrombin inhibitors
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
EP1488046A4 (en) CONSTRUCTION METHODS
GB0223276D0 (en) Cladding of rails
AU2003215298A1 (en) Alpha1beta1 antagonists for treatment of atherosclerosis
IL161521A0 (en) N-formyl derivatives of paroxetine
AU2003299137A8 (en) Inhibition of metallo-beta-lactamase
AU2003304374A8 (en) Peptide inhibitors of beta-lactamases
PL376796A1 (pl) Sposób wytwarzania inhibitorów fosfodiesterazy-4
AU2003223329A8 (en) Antagonists of rf-amide neuropeptides
GB0204088D0 (en) Novel substituted heterocyclic inhibitors of catechol-o-methyl transperase
GB0225854D0 (en) Inhibitors of complement activation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180807